EUVIMEDEUVIMED entdecken
Multizentrische Studie

Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

Chen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, Chi-Yi Chen, Ching-Chu Lo, Kuo-Chih Tseng, Pei-Yuan Su, Wei-Yu Kao, Ming-Chang Tsai, Hung-Da Tung, Hao-Tsai Cheng, Fu-Jen Lee und 19 weitere

Hepatology International · 2023

DOI: 10.1007/s12072-022-10475-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hepatology International, 2023. Verfasst von Chen-Hua Liu und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Hepatitis C. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Real-world data are scarce about the effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for retreating East Asian patients with hepatitis C virus (HCV) infection who previously received NS5A direct-acting antivirals (DAAs). We conducted a multicenter study to assess the performance of SOF/VEL/VOX in patients who were not responsive to prior NS5A inhibitors in Taiwan. METHODS: Between September 2021 and May 2022, 107 patients who failed NS5A inhibitor-containing DAAs with SOF/VEL/VOX salvage therapy for 12 weeks were included at 16 academic centers. The sustained virologic response at off-treatment week 12 (SVR12) was assessed in the evaluable (EP) and per-protocol (PP) populations. The safety profiles were also reported. RESULTS: All patients completed 12 weeks of treatment and achieved an end-of-treatment virologic response. The SVR12 rates were 97.2% (95% confidence interval (CI) 92.1-99.0%) and 100% (95% CI 96.4-100%) in EP and PP populations. Three (2.8%) patients were lost to off-treatment follow-up and did not meet SVR12 in the EP population. No baseline factors predicted SVR12. Two (1.9%) not-fatal serious adverse events (AE) occurred but were unrelated to SOF/VEL/VOX. Sixteen (15.0%) had grade 2 total bilirubin elevation, and three (2.8%) had grade 2 alanine transaminase (ALT) elevation. Thirteen (81.3%) of the 16 patients with grade 2 total bilirubin elevation had unconjugated hyperbilirubinemia. The estimated glomerular filtration rates (eGFR) were comparable between baseline and SVR12, regardless of baseline renal reserve. CONCLUSIONS: SOF/VEL/VOX is highly efficacious and well-tolerated for East Asian HCV patients previously treated with NS5A inhibitor-containing DAAs. CLINICAL TRIALS REGISTRATION: The study was not a drug trial. There was no need for clinical trial registration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicHepatitis CHumansSofosbuvirAntiviral AgentsTaiwanHeterocyclic Compounds, 4 or More RingsSustained Virologic ResponseHepacivirusGenotypeAminoisobutyric AcidsCyclopropanesLeucineProlineQuinoxalinesSulfonamidesLactams, MacrocyclicBenzimidazolesBenzopyransCarbamates

Stichwörter der Autor:innen

Direct-acting antiviralEffectivenessHepatitis C virusPangenotypicResistance-associated substitutionSafetySofosbuvirSustained virologic responseVelpatasvirVoxilaprevir

Substanzen

SofosbuvirAntiviral AgentsHeterocyclic Compounds, 4 or More RingsvoxilaprevirAminoisobutyric AcidsCyclopropanesLeucineProlineQuinoxalinesSulfonamides

Autor:innen und Institutionen

  • Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Yunlin, Taiwan.
  • Department of Internal Medicine, Center for Digestive Medicine, China Medical University Hospital, Taichung, Taiwan.
  • School of Medicine, China Medical University, Taichung, Taiwan.
  • Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine Hospital, Taipei, Taiwan.

Zitieren

APA

Liu, C. H., Peng, C. Y., Liu, C. J., Chen, C. Y., Lo, C. C., Tseng, K. C., Su, P. Y., Kao, W. Y., Tsai, M. C., Tung, H. D., Cheng, H. T., Lee, F. J., Huang, C. S., Huang, K. J., Shih, Y. L., Yang, S. S., Wu, J. H., Lai, H. C., Fang, Y. J., …, & Kao, J. H. (2023). Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan. Hepatology International. https://doi.org/10.1007/s12072-022-10475-9

Vancouver

Liu CH, Peng CY, Liu CJ, Chen CY, Lo CC, Tseng KC, et al. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan. Hepatology International. 2023. doi:10.1007/s12072-022-10475-9

BibTeX
@article{Liu2023,
  author = {Liu, Chen-Hua and Peng, Cheng-Yuan and Liu, Chun-Jen and Chen, Chi-Yi and Lo, Ching-Chu and Tseng, Kuo-Chih and Su, Pei-Yuan and Kao, Wei-Yu and Tsai, Ming-Chang and Tung, Hung-Da and Cheng, Hao-Tsai and Lee, Fu-Jen and Huang, Chia-Sheng and Huang, Ke-Jhang and Shih, Yu-Lueng and Yang, Sheng-Shun and Wu, Jo-Hsuan and Lai, Hsueh-Chou and Fang, Yu-Jen and Chen, Po-Yueh and Hwang, Jow-Jyh and Tseng, Chi-Wei and Su, Wei-Wen and Chang, Chun-Chao and Lee, Pei-Lun and Chen, Jyh-Jou and Chang, Chi-Yang and Hsieh, Tsai-Yuan and Chang, Chung-Hsin and Huang, Yi-Jie and Kao, Jia-Horng},
  title = {Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan},
  journal = {Hepatology International},
  year = {2023},
  doi = {10.1007/s12072-022-10475-9}
}
Kostenlos starten →